Market Research Logo

Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028

In 2017, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research approved 46 novel drugs, out of which 34 were small molecules. Moreover, it is important to acknowledge that the present pipeline of pharmaceutical products is increasingly complex and requires specialized facilities, equipment and operational expertise. In addition, the costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. The aforementioned constraints have led many of the smaller players in the industry and, at times, certain pharma giants as well, to outsource a significant part of their business operations to contract service providers. Such third-party service providers are known to offer significant cost-benefits, access to larger production capacities and reductions in time-to-market. Over the years, the contract manufacturing market has grown into a prominent and promising segment of the overall pharmaceutical industry. In fact, post 2000, more than 138 new CMOs have been established, offering cost-efficient solutions to several stakeholders in the industry.

It is worth mentioning that the current global CMO market is highly fragmented but characterized by multiple acquisitions and mergers as stakeholders strive to broaden their respective service portfolios. In fact, this has enabled several CMOs to start offering end-to-end services across the entire value chain, from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings. However, given the ongoing innovation in production technologies and the steadily evolving pipeline of small molecules, the pressure on the contract manufacturing industry is expected to increase in the coming years. This is likely to require CMOs to devise and implement different business strategies and models in order to cope with the evolving demand.

The ‘Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028’ report provides a comprehensive study on the current scenario of contract manufacturing services related to pharmaceutical products. The study features an in-depth analysis, highlighting the capabilities of a diverse set of pharmaceutical CMOs. Amongst other elements, the report features:

An overview of the current market landscape, featuring a comprehensive list of over 500 active CMOs, and detailed analysis of manufacturing service providers based on a number of parameters, such as geographical location of CMOs, type of business segments (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), type of FDFs manufactured (solids, liquids / semi-solids and injectables), scale of operation (pilot, clinical, and commercial), type of service(s) offered, specific location of manufacturing facilities (country-wise) and types of primary packaging forms being manufactured (tablet / capsule / blister packing, ointment / gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe). In addition, the report features a year-wise analysis of the number of CMOs that have been established over the past five decades, based on the year in which they were founded.

An analysis of the most active regions, based on the presence of contract manufacturers; the report contains schematic world map representations indicating the geographical location of key hubs with respect to contract manufacturing activity across the globe.

A detailed discussion of various guidelines laid down by major regulatory bodies in different countries. The report also includes a comprehensive assessment of over 500 CMOs, including details of operational approvals and certifications received by each firm. In addition, the report highlights the relative popularity of the key regulatory bodies across the globe based on the number of companies which comply to the guidelines laid down by each of these authorities. The report also features an insightful multi-dimensional bubble analysis, featuring a comparison of the current regulatory scenario in key geographies across the globe.

Elaborate profiles of key players that offer end-to-end services ranging from product design and discovery to final packaging. Each profile provides an overview of the company, its financial performance (if available), information on its service(s) portfolio, manufacturing facilities and capabilities, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.

A case study comparing the key characteristics of large molecule and small molecule drugs, along with the steps involved in their respective manufacturing processes. In addition, it provides an overview of the current biopharmaceutical contract manufacturing landscape, featuring a list of over 200 CMOs that are currently offering contract manufacturing services for large molecules.

A comprehensive set of analyses on pharmaceutical contract manufacturing service providers featuring three schematic representations, which include [A] a heat map analysis featuring the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of location of headquarters, year of establishment and number of employees, [B] a geographical landscape analysis, highlighting those CMOs that have a significantly wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees and the type of business operation.

A detailed capacity analysis, based on global, market wide research on the individual development and manufacturing capacities of various stakeholders in the industry. The analysis takes into consideration the actual capacities of small-sized, mid-sized, large and very large CMOs, and is based on robust data collection done via both secondary and primary research. The study highlights the distribution of global capacity by scale of operation (clinical, commercial, both), regions (North America, Europe, Asia-Pacific, rest of the world) and specific countries within North America (the US, Canada and Mexico), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, Australia and rest of Asia) and rest of the world.

A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution. It also offers a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.

A review of emerging trends, including the increase in outsourcing activity in emerging markets, shift towards an integrated business model through expansions and consolidation, introduction of innovative technologies / continuous processing systems, use of big data and advanced analytics to improve the manufacturing process and adoption of cybersecurity solutions to protect confidential customer data. It also includes a detailed discussion on the various growth drivers, such as increasing demand for biologics, biosimilars, and highly potent and cytotoxic drugs.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the pharmaceutical contract manufacturing market over the coming decade. Based on various parameters, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2028. In addition, we have provided the likely distribution of the market based on [A] type of business segment (API and FDF), [B] regional evolution of the market covering North America (the US, Canada and Mexico), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, Australia and rest of Asia) and rest of the world, [C] type of API product (branded and generic) within the aforementioned regions, [D] type of FDFs manufactured (solids, liquids / semi-solids and injectables), [E] type of packaging forms (tablet / capsule / blister packing, ointment / gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe), [F] scale of API manufacturing (clinical, commercial, and both) and [G] size of manufacturers (small sized, mid-sized, large and very large companies). To account for the uncertainties associated with the growth of pharmaceutical contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. This enabled us to solicit inputs on upcoming opportunities and challenges that were considered to develop estimates for a more inclusive growth. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following stakeholders:

Scott Goldstein (Associate Director, Drug Product Manufacturing, Ajinomoto Althea)
Thomas Früh (Chief Executive Officer, Bachem)
Piyush Desai (Director-Operations, Sovereign Pharma)
Claire Otjes (Assistant Marketing Manager, Batavia Biosciences)
Dietmar Katinger (CEO, Polymun Scientific)
Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie)
Sebastian Schuck (Head of Business Development, Wacker Biotech)
Bhaskar Venepalli (President and Chief Executive Officer, CiVentiChem)
Roberto Margarita (Business Development Director, CordenPharma)
Allison Vavala (Senior Manager, Business Development, Helsinn)
Kevin Daley (Market Director Pharmaceuticals, Novasep)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. Over 500 companies across the world are currently offering pharmaceutical contract manufacturing services. Service providers offer a variety of pharmaceutical services; these range from formulation services, stability studies / stability testing, method development / analytical development / process development, clinical trial material manufacturing, scale-up, registration batch manufacturing, commercial production and packaging and labelling service. It is worth highlighting that several CMOs offer end-to-end services across all scales of operations; examples of such players include (in alphabetical order) Aenova, Alcami® Pharma, AMRI, Catalent®, CMIC Group, CordenPharma, Dalton Pharma Services, Fresenius Kabi, Hovione, Recipharm, Siegfried Group and WuXi AppTec.

2. At present, the market is highly fragmented and is a mix of established companies (>200 employees, 52%), mid-sized companies (>50 employees, 26%) and small-sized companies (<50 employees, 21%) offering contract manufacturing services at various scales of operations. 46% of the companies are specifically providing FDF manufacturing services while 23% are specifically providing API manufacturing services. The remaining 31% of the companies offer both API and FDF contract manufacturing services.

3. Regulatory authorities play an active role in making pharmaceutical industry one of the most highly regulated industries across the world. We observed that 79% of the CMOs have received operational approval and certification from the USFDA. This is followed by the companies that have received operational approval from the European Medicines Agency (33%), World Health Organization (30%) and UK Medicines and Healthcare products Regulatory Agency (20%). In addition, several CMOs have sought / received operational approval and certification from the regulatory bodies in other regions such as Australia, Brazil, China, Canada, India and South Africa.

4. The current global contract pharmaceutical installed manufacturing capacity is estimated to be over 115 million liters. It is also worth mentioning that, amongst all the CMOs we evaluated, established CMOs contribute a significant proportion (78%) to the overall supply. Having said that, relatively small-sized or mid-sized companies are one of the key driving forces behind the heightened pace of pharmaceutical research and development. In addition, of the total installed capacity, over 75% of the total installed capacity is being used for both clinical and commercial production.

5. Amidst increasing competition in the outsourcing domain, CMOs are actively investigating and adopting several innovative tools and strategies in order to advance the development of drugs with higher success rates and improve the overall productivity. Examples of such strategies (in no specific order) include usage of big data analytics, green chemistry (such as solvent reduction and replacement, refining a chemical route and biocatalysis to optimize API synthesis), continuous process manufacturing system, digital medicines, 3D printed pill technologies, robotics and automation instruments for packaging, adoption of improved waste management and environment friendly strategies along with the integration of cybersecurity solutions.

6. Driven by increasing global demand and rapid approval of small molecule drugs by the USFDA, we expect the overall contract manufacturing market in the pharmaceutical domain to grow at an annualized rate of 4.8% between 2018 and 2028. The growth is likely to be higher in emerging markets of Asia-Pacific and rest of the world.

7. In terms of type of API product (branded and generic), generic APIs hold the current major share of the market (84%) while the remaining share (16%) of the total outsourced API market is occupied by branded APIs. Within the contract FDF market, solid dose compounds (~50%) currently dominate the market followed by injectables (33%) and semi-solid / liquid compounds (17%). The future growth is likely to be driven by injectables dose manufacturing primarily due to increased focus on complex disease areas and the growing trend of self-administration.

8. In terms of type of FDF, the most popular type is primary packaging of tablets / capsules / blisters, which currently hold 26% of the total FDF contract manufacturing market. This is further followed by glass / plastic / dropper bottles (21%) and vials / cartridge (15%). Other packaging forms such as ampoules, ointments / gels / tubes and sachets / pouches / infusion bags also hold a considerable share of the current FDF contract manufacturing market.

9. North America currently holds the largest share (34.3%) in the overall contract manufacturing market and is anticipated to continue to grow at an annualized growth rate of 2.9%. This is followed by Asia-Pacific and Europe that account for 34.1% and 30.3% share of the overall contract manufacturing market, respectively. However, markets in Asia-Pacific are expected to grow at a significantly higher CAGR of 7.1%, owing to inherent advantages such as relatively low labor costs and less stringent regulatory constraints.

1.1. RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

1.1. CHAPTER OUTLINES
Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of pharmaceutical contract manufacturing market, in the short-mid and long term.

Chapter 3 is a general introduction to various type of manufacturers in the pharmaceutical market. It features a brief overview of the concept of contract manufacturing and a general discussion on the evolution of the contract services in the pharmaceutical industry. It also includes a detailed discussion on the need for outsourcing in this domain. Further, we have provided a brief overview of contract manufacturing models that have been adopted in the pharmaceutical industry, till date. We have also presented an exhaustive list of services offered by CMOs; the chapter concludes with a discussion on the challenges associated with the market.

Chapter 4 provides a comprehensive view on the global landscape of pharmaceutical CMOs. It includes information related to over 500 CMOs that are currently active in the pharmaceutical industry. It features an in-depth market review, including regional distribution, analysis by company size and year of establishment, type of business segments, type of FDFs manufactured, scale of operation, type of service(s) offered, location of manufacturing facilities and different types of primary packaging forms being manufactured.

Chapter 5 features a detailed discussion on the guidelines laid down by major regulatory bodies across different countries. The report also includes an assessment of over 500 CMOs related to the operational approvals and certifications received from various regulatory bodies, along with a schematic world map representation, highlighting the relative popularity (in terms of the number of companies that are operating in compliance to the guidelines laid down by each regulatory authority) of the key regulatory bodies across the globe. In addition, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies across the globe.

Chapter 6 features detailed profiles of some of the key players that are active in the pharmaceutical contract manufacturing market and are acting as one-stop-shops. Each profile presents a brief overview of the company, its financial information (if available), details related to its service(s) portfolio, manufacturing facilities and capabilities, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.

Chapter 7 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes. In addition, it provides an overview of the current biopharmaceutical contract manufacturing landscape, featuring a list of over 200 CMOs that are offering contract manufacturing services for large molecules / biologics.

Chapter 8 presents a collection of key insights derived from the study. It includes a heat map analysis, highlighting the number of integrated players based on the location of their headquarters, year of establishment and number of employees. The chapter also features a geographical landscape analysis, wherein pharmaceutical CMOs having a relatively wide geographical reach, are highlighted. For this analysis, we have also highlighted the geographical locations of the aforementioned companies on a world map. In addition, the chapter includes a schematic grid analysis, featuring the distribution of pharmaceutical CMOs based on location of their headquarters, number of employees and the type of business operations (API / FDF / both).

Chapter 9 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of pharmaceutical products. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small-sized, mid-sized, large and very large CMOs, distributed across their respective facilities. The results of this analysis were used to establish an accurate opinion on outsourcing capabilities of the CMOs across different geographies / regions and scales of operation (clinical, commercial and both). Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.

Chapter 10 provides a comprehensive market forecast analysis, highlighting the future potential of pharmaceutical contract manufacturing till the year 2028. It features the likely distribution of the market based on [A] type of business segment (API and FDF), [B] region (North America, Europe, Asia-Pacific and rest of the world) and further distribution by major countries within the aforementioned regions, [C] type of API product (branded and generic) within the aforementioned regions, [D] type of FDFs manufactured (solids, liquids / semi-solids and injectables), [E] type of packaging forms (tablet / capsule / blister packing, ointment / gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe), [F] scale of API manufacturing (clinical, commercial, and both) and [G] size of manufacturers (small sized, mid-sized, large and very large-companies).

Chapter 11 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under a comprehensive SWOT framework. The chapter also highlights a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall pharmaceutical industry.

Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters. It also provides a brief overview of some of the upcoming future trends, which, we believe, are likely to influence the growth of pharmaceutical CMOs in the foreseen future.

Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Scott Goldstein (Associate Director, Drug Product Manufacturing, Ajinomoto Althea), Thomas Früh (Chief Executive Officer, Bachem), Piyush Desai (Director-Operations, Sovereign Pharma), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), Dietmar Katinger (CEO, Polymun Scientific), Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Sebastian Schuck (Head of Business Development, Wacker Biotech), Bhaskar Venepalli (President and Chief Executive Officer, CiVentiChem), Roberto Margarita (Business Development Director, CordenPharma), Allison Vavala (Senior Manager, Business Development, Helsinn), Kevin Daley (Market Director Pharmaceuticals, Novasep).
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report:
1. 3P Biopharmaceuticals
2. A&Z Pharmaceutical
3. A.S. Joshi & Company
4. Aalto Scientific
5. Aarti Industries
6. Abbott
7. AbbVie
8. ABL
9. Abzena
10. Accra Pac India
11. ACES Pharma
12. Acino International
13. ACS Dobfar
14. Actiza Pharmaceutical
15. Adar Biotech
16. Admac Formulations
17. Aenova
18. Aesica Pharmaceuticals
19. Affinity Life Sciences
20. Afton Scientific
21. Agno Pharma
22. AiPing Pharmaceutical
23. Air Water
24. Ajinomoto Althea
25. Ajinomoto OmniChem
26. Akorn
27. Akums Drugs & Pharmaceuticals
28. Al Bahja Group
29. Aland (Jiangsu) Nutraceutical
30. Albany Molecular Research (AMRI)
31. Albatros Pharmaceuticals
32. Albemarle
33. AlbyPharma
34. Alcami
35. Alcatel-Lucent
36. Aldevron
37. Alembic Pharmaceuticals
38. Alkermes®
39. AllChem Laboratories
40. Alliance Medical Products
41. Almac Pharma
42. Alpax Pharmaceutical
43. Alphora Research
44. Alps Pharmaceutical
45. Altaris Capital Partners
46. ALTHEA Pharma
47. Amanta Healthcare
48. Amatsigroup
49. Ambica Pharma Sales
50. AmbioPharm
51. AMEGA Biotech
52. American Antibiotics
53. Amgen®
54. Ami Lifescience
55. Amman Pharmaceutical Industries
56. Amneal Pharmaceuticals
57. Amoli Organics
58. AMPAC Fine Chemicals
59. Angelini
60. Anhui Biochem United Pharmaceutical
61. Ankur Drugs and Pharma
62. Anogen
63. Anqiu Lu'an Pharmaceutical
64. apceth Biopharma
65. Apex Pharmaceuticals
66. Apicore Pharmaceuticals
67. Apiscent Labs
68. APL
69. Apotex Fermentation
70. Aptuit
71. Arabio
72. Arbro Pharmaceuticals
73. Arch Pharmalabs
74. Arevipharma
75. Arran Chemical Company
76. Arvincare
77. Asahi Glass Company (AGC)
78. Asahi Kasei Finechem
79. Ashford Pharmaceutical Laboratories
80. Aspen Pharmacare Holdings
81. Aster Pharma
82. Asymchem Laboratories
83. ATRA Pharmaceuticals
84. AURA Biotechnologies
85. Aurelius
86. Aurobindo Pharma
87. Ausler Snovy Healthcare
88. AustarPharma
89. Austin Pharmaceuticals
90. AutekBio
91. Avecia
92. Avid Bioservices
93. Avra Laboratories
94. Avyukt Pharmaceuticals
95. Axa Parenterals
96. Baccinex
97. Bachem
98. Bal Pharma
99. Batavia Biosciences
100. Bausch & Lomb
101. Baxil Pharma
102. Baxter BioPharma Solutions
103. Bayer
104. BCN Peptides
105. Beach Products
106. Becton Dickinson
107. Beijing Second Pharmaceutical
108. Belcher Pharmaceuticals
109. Belco Pharma
110. Beltapharm
111. Bennet Pharmaceuticals
112. BePharBel
113. Beximco Pharmaceuticals
114. Bharat Pharmaceuticals
115. Bharat Serums and Vaccines
116. BIBITEC
117. BINEX
118. Bio Elpida
119. BioCell
120. BioClin Laboratories
121. Biocon
122. BioConnection
123. BIOFABRI
124. Bio-Garten
125. Biogen
126. Biological E
127. BioMARC
128. Biomatik
129. Biomay
130. BIOMEVA
131. Bio-Pharm
132. BioPharmaceuticals Australia
133. Bioserv
134. BioSynergy
135. Bio-Synthesis
136. Biotech Vision Care
137. BioTechLogic
138. BioTechnique™
139. Biotechpharma
140. Biovectra
141. Biovian
142. Bluepharma
143. Blueprint Medicines
144. Boehringer Ingelheim BioXcellence
145. Bonarum Pharma
146. Brammer Bio
147. Brassica Pharma
148. Brazilian Health Regulatory Agency (ANVISA)
149. Broad Institute of MIT and Harvard
150. Broad Pharmaceutical
151. Bruker Daltonics
152. Bruschettini
153. Bryllan
154. BSP Pharmaceuticals
155. C & O Pharmaceutical Technology
156. Cadila Pharmaceuticals
157. Calyx Chemicals & Pharmaceuticals
158. Cambrex
159. Capgemini
160. Caplin Point Laboratories
161. Capsugel®
162. CARBOGEN AMCIS
163. Catalent®
164. Cayman Chemical
165. Cell and Gene Therapy Catapult
166. Cell Culture Company
167. Cell Essentials
168. Cell Therapies
169. CELLforCURE
170. Cellin Technologies
171. Celltech
172. Celltrion
173. Cellular Therapeutics
174. Celonic
175. Cenexi
176. Centaur Pharmaceuticals
177. Center for Biocatalysis and Bioprocessing, The University of Iowa
178. Central Drugs Standard Control Organization (CDSCO)
179. Century Pharmaceuticals
180. CEPiA Sanofi
181. Cerbios-Pharma
182. CF Pharma
183. Charles River Laboratories
184. Chartwell Pharmaceuticals
185. ChemCon
186. Chemi Peptides
187. Chemigran
188. ChemPacific
189. ChemPartner
190. Cherokee Pharma
191. Chifeng Arker Pharmaceutical Technology
192. China Chemical & Pharmaceutical (CCPC)
193. China Food and Drug Administration (CFDA)
194. Chiral Biosciences
195. Chirogate International
196. Chongqing Huapont Pharmaceutical
197. Chromo Laboratories
198. Chunghwa Chemical Synthesis & Biotech
199. CinnaGen
200. Ciron Group
201. Cirrus Pharmaceuticals
202. CiVentiChem
203. Clinical Trial Consultants (CTC)
204. Cloud Holdings
205. CMC Biologics
206. CMC Milling
207. CMIC Group
208. Coating Place
209. Cobra Biologics
210. COC Farmaceutici
211. Cody Laboratories
212. Cognate BioServices
213. Columbia University
214. Combino Pharm
215. Comprehend Systems
216. Concord Biotech
217. Concord Drugs
218. Confab Laboratories
219. Contract Coating
220. Contract Pharmacal
221. Cook Pharmica
222. Corden BioChem
223. CordenPharma
224. CoreRx®
225. CP Pharmaceuticals
226. Creative® Biolabs
227. CRELUX
228. Cris Pharma
229. Crown Laboratories
230. CTX Lifesciences
231. Custom Pharmaceuticals
232. Cyalume® Speciality Products
233. Cytovance® Biologics
234. Daiichi Sankyo
235. Daito Pharmaceutical
236. Dalton Pharma Services
237. Delavau Pharmaceutical Partners
238. Delmar Chemicals
239. Delpharm
240. Delta Laboratories
241. Dermopartners
242. DEVA Holding
243. DFB Pharmaceuticals
244. Dhruv Life Sciences
245. Dipharma Francis
246. Dishman Group
247. Divis Laboratories
248. DM Pharma
249. dmBio
250. DOTTIKON EXCLUSIVE SYNTHESIS
251. Douglas Pharmaceuticals
252. DPT® Laboratories
253. Dr. Reddy's Custom Pharmaceutical Services (CPS)
254. Dupen Laboratories
255. Dwarkesh Pharmaceuticals
256. Eagle Pharmaceuticals
257. Eden Healthcare
258. Ei-A Pharmaceutical SolutionWorks™
259. EirGen Pharma
260. EirGenix
261. EL Laboratories
262. Elite Pharmaceuticals
263. Elli Lilly
264. Embio
265. Emcure Pharmaceuticals
266. Emergent Biosolutions®
267. Eminent Healthcare
268. Enaltec Labs
269. Encap Drug Delivery
270. Enrich Pharma
271. Entema Laboratorios
272. Entod Pharmaceuticals
273. Epic Pharma
274. EPTEK Technology
275. Ercros
276. Eriochem
277. Erregierre
278. Esteve Química
279. Ethypharm
280. EuBiologics
281. EUCODIS Bioscience
282. EUFETS
283. Eurogentec
284. Euro-Med Laboratories
285. European Medicines Agency (EMA)
286. Euticals
287. Evonik Industries
288. Evotec
289. Excella
290. Exela Pharma Sciences
291. Exostar
292. Exova SL Pharma Labs
293. F.I.S. Fabbrica Italiana Sintetici
294. Famar
295. Famy Care
296. Fareva®
297. Farmabios®
298. Farmak
299. Farmhispania Group
300. Farmigea
301. FDC
302. Fermion
303. Ferndale Laboratories
304. Finecure Pharmaceuticals
305. FineTech Pharmaceuticals
306. Flamingo Pharmaceuticals
307. Flamma
308. Fleming Laboratories
309. Fluid Energy Processing and Equipment
310. Fresenius Kabi
311. Fresenius Kabi Product Partnering
312. FUJIFILM Diosynth Biotechnologies
313. Fujimoto Chemicals
314. Fusion Antibodies
315. Future Pak
316. G&W Laboratories
317. Gadea Pharmaceutical Group
318. Gala Biotech
319. Galentic Pharma
320. Gattefossé
321. GD Pharma
322. GE Healthcare
323. Gedeon Richter
324. Gemini PharmChem Mannheim
325. Gene Transfer Vector Core (GTVC)
326. GeneCure Biotechnologies
327. Genentech
328. GenIbet Biopharmaceuticals
329. Gerresheimer
330. Getz Pharma Research
331. Gland Pharma
332. Glatt®
333. GlaxoSmithKline (GSK)
334. Glenmark Pharmaceuticals
335. Global Pharmatech
336. Glochem Industries
337. Glycotope Biotechnology
338. GNH India
339. goBalto
340. Goodwin Biotechnology
341. GP Pharm
342. Grand River Aseptic Manufacturing
343. Granules India
344. Granules Omnichem
345. GreenPak Biotech
346. Grindeks
347. Groupe PARIMA
348. Groupe SYNERLAB
349. Grupo Farmasierra
350. GTCR
351. GTP Technology
352. Guardian Drug Company
353. Hainan Poly Pharm
354. Hainan Visum Pharmaceutical
355. HALIX
356. Halo Pharma
357. Handok
358. Hanford Pharmaceuticals
359. Hangzhou Hysen Pharma
360. Hangzhou Imaginechem
361. Hangzhou Panyu Chemical
362. Hanuchem Laboratories
363. HD Biosciences
364. Health Biotech
365. Health Canada
366. Healthcare Pharmaceuticals
367. Healthy Life Pharma
368. Helios Pharmaceuticals
369. Helsinn Group
370. Hetero Drugs
371. Hewlett-Packard®
372. HighRes Biosolutions
373. Hikal
374. Hikma Pharmaceuticals
375. Histocell
376. hollomet®
377. Hong Kong Institute of Biotechnology
378. Honson Pharmatech Group
379. Horizon Pharma
380. Hospira One2One
381. Hovione
382. Howard Hughes Medical Institute (HHMI)
383. Hritik Chemicals
384. Hubei Biocause Pharmaceutical
385. IBM®
386. Icagen
387. ICROM
388. IDT Australia
389. IDT Biologika
390. Illumina
391. Indena
392. Indian Immunologicals
393. Indoco Remedies
394. Ind-Swift Laboratories
395. Ingenus Pharmaceuticals
396. Inke
397. Inno Biologics
398. Innova Captab
399. Institute for Advanced Study (IAS)
400. INSYS Therapeutics
401. Intas Pharmaceuticals
402. Integrity Bio
403. International Chemical Investors Group (ICIG)
404. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)
405. Interquim
406. Invent Farma
407. inVentiv Health
408. IPC Process-Center
409. i-Pharmaceuticals
410. Istituto Biochimico Italiano Giovanni Lorenzini
411. IVAX Pharmaceuticals
412. J.B. Chemicals & Pharmaceuticals
413. Janssen Pharmaceuticals
414. Japan CMO Association (JCMOA)
415. JGL
416. JHL Biotech
417. Johnson & Johnson
418. Johnson Matthey
419. JSC Olainfarm
420. Jubilant Life Sciences
421. Julphar Gulf Pharmaceutical Industries
422. Juno Therapeutics
423. JW Biotechnology
424. Jyoti Capsulations
425. KABS Pharmaceutical Services
426. Kamat Pharmatech
427. Kancera
428. Karolinska University Hospital
429. Katsura Chemical
430. KBI Biopharma
431. Kekule Pharma
432. Kemwell Biopharma
433. Keryx Biopharmaceuticals
434. Kilitch Healthcare
435. Kongo Chemical
436. Korten
437. KP Pharmaceutical Technology
438. Krebs Biochemicals & Industries
439. KRS Global Biotechnology
440. Kyowa Pharma Chemical
441. Laboratório Edol
442. Laboratorios Farmacéuticos ROVI
443. Laboratorios Lesvi
444. Laboratorios SALVAT
445. Laccure
446. Lameplast Group
447. LAMPIRE Biological Laboratories
448. Lannett
449. Laurus Labs
450. Lenovo™
451. Lenus LifeCare
452. LFB BIOMANUFACTURING
453. LIDDS™
454. Life Sciences Solutions
455. Life Technologies™
456. Lifekyor Pharmaceuticals
457. Lloyd Laboratories
458. LOBA Feinchemie
459. Logos Pharma
460. Lomapharm®
461. Long Pharmaceuticals
462. Lonza
463. LSNE Contract Manufacturing
464. Luina Bio
465. Luitpold Pharmaceuticals
466. Lyne Laboratories
467. MabPlex
468. MacFarlan Smith
469. Macter International
470. Madras Pharmaceuticals
471. Maine Biotechnology Services
472. MAKCUR Laboratories
473. Malik Lifesciences
474. Malladi Drugs & Pharmaceuticals
475. Manav Drugs
476. Marchesini Group
477. Marksans Pharma
478. Massachusetts Institute of Technology
479. MassBiologics
480. MaSTherCell
481. Maxcure Nutravedics
482. Maya Biotech
483. Mayne Pharma Group
484. McGuff Pharmaceuticals
485. MDC Pharmaceuticals
486. Meda Pharmaceuticals
487. Medical Products Laboratories
488. Medichem
489. Medicines and Healthcare products Regulatory Agency (MHRA)
490. Medicines Control Council (MCC)
491. Medilux Laboratories
492. Mediwin Pharmaceuticals
493. Medix Biochemica
494. MedPharm
495. Menadiona
496. Menarini Biotech
497. Mercator Pharmaceutical Solutions
498. Merck
499. Meridian Life Science
500. Meridian Medicare
501. Merro Pharmaceutical
502. Metrics Contract Services
503. Metrochem API
504. Micro Labs
505. MicroBiopharm Japan
506. Micro-Sphere
507. Mikart
508. Ministry of Food and Drug Safety (MFDS)
509. Ministry of Health, Labour and Welfare (MHLW)
510. Mipharm
511. Mitim
512. MSN Laboratories
513. Multi-Pack Solutions
514. Murty Pharmaceuticals
515. Mycenax Biotech
516. Mylan®
517. Nakoda Chemicals
518. Nanjing Pharmatechs
519. NATCO Pharma
520. National Center for Advancing Translational Sciences
521. National Institutes of Health
522. Nectar Lifesciences
523. NEISS Labs
524. Nephron Pharmaceuticals
525. NerPharMa
526. Neuland Laboratories
527. New York Center for Nanomedicine Research
528. Nexgen Pharma
529. Nextar Chempharma Solutions
530. Nimbles Biotech
531. Ningbo Renjian Pharmaceutical Group
532. Nippon Rika Technologies
533. Nipro Patch
534. Nitin Lifesciences
535. Nitto Avecia Pharma Services
536. Nitto Denko Avecia
537. Nivon Specialties
538. Norac Pharma
539. North Star Processing
540. Norwegian Institute of Public Health
541. Norwich Pharma Services
542. Nova Laboratories
543. NovaMed Pharmaceuticals
544. Novartis
545. Novasep
546. Novel Laboratories
547. Novex Innovations
548. Nutragen Pharma
549. NutraLab
550. NVRON Life Science
551. Oakwood Laboratories
552. Oasis Laboratories
553. Oceanic Pharmachem
554. OctoPlus
555. Olon
556. Oman Pharmaceutical Products
557. Omnia Biologics
558. Onco Generics
559. Oncotec Pharma Produktion
560. OPKO Health
561. Optel Vision
562. Orchid Pharma
563. Orient EuroPharma
564. Orient Pharma
565. Orion
566. Orofino Pharmaceuticals Group
567. Oso BioPharmaceuticals Manufacturing
568. Oxford BioMedica
569. P&R Holding
570. Pan American Health Organization (PAHO)
571. Panacea Biotec
572. PannonPharma
573. Parabolic Drugs
574. Paragon® Bioservices
575. Particle Sciences
576. Patheon®
577. PB-L Productos Bio-Lógicos
578. PCI Synthesis
579. PCT Cell Therapy
580. Pegasus Farmaco India
581. Penn United Industries
582. Perrigo®
583. Pfizer
584. Pfizer CentreOne
585. Pharma Stulln
586. PharmaCell
587. Pharmaceutical Associates
588. Pharmaceutical Manufacturing Research Services (PMRS)
589. Pharmaceutical Medical Devices Agency (PMDA)
590. Pharmaceutics International (Pii)
591. Pharmacia & Upjohn
592. PharmAgra Labs
593. Pharma-Q
594. Pharmascience
595. Pharmasol
596. Pharmatronic
597. PharmaZell
598. Pharmedartis
599. Pharmer
600. Pharmicell
601. Phenom-World
602. Phytex Australia
603. Phyton Biotech
604. Pierre Fabre
605. Pillar5 Pharma
606. Pinewood Healthcare
607. Piramal Pharma Solutions
608. PiSA Farmaceutica
609. Pisgah Laboratories
610. PlasmidFactory
611. PMC Isochem
612. Polpharma
613. Polymun Scientific
614. PolyPeptide Group
615. Polysciences
616. Porton Fine Chemicals
617. Praxis Pharmaceutical
618. Precision Antibody
619. Preet Remedies Group
620. PREMAS Biotech
621. Prima BioMed
622. PrimaPharma
623. Prisha Healthcare
624. ProBioGen
625. Procaps
626. Procos
627. Profectus BioSciences
628. ProJect Pharmaceutics
629. ProMab Biotechnologies
630. Proton Pharma
631. Provizer Pharma
632. PRWT Services
633. PT. ETHICA Industri Farmasi
634. Pure & Cure Healthcare
635. PX'Therapeutics
636. Pyramid Laboratories
637. QS Pharma
638. Qualigen
639. Qualiphar-Gifrer
640. Qualitron Bio Medica
641. Quality Chemical Laboratories
642. Qualtra Pharmaceuticals
643. Quay Pharma
644. Que Pharma
645. Radico Remedies
646. Rafarm
647. Ramsey Design Group
648. Rank Group
649. Recipharm
650. Redwing Pharma
651. Regis Technologies
652. Reliable Biopharmaceutical®
653. Reliance Life Sciences
654. Remington Pharmaceuticals
655. Renaissance Acquisition Holdings
656. Rentschler Biopharma
657. ResearchPoint Global
658. Richter-Helm BioLogics
659. RiconPharma
660. RIVOPHARM
661. RL Fine Chem
662. Robert Wood Johnson Medical School
663. Roche
664. Rommelag
665. Rompharm
666. Roslin Cell Therapies
667. Rottendorf Pharma
668. Rubicon Research
669. Rusan Pharma
670. SAFC Pharma™
671. SAI Life Sciences
672. Salvus Pharma
673. Sandoz
674. Sanico
675. SANOCHEMIA Pharmazeutika
676. Sanquin Pharmaceutical Services
677. Sanwa Kagaku Kenkyusho
678. Sarvodaya Drugs & Pharmaceuticals
679. Sarvotham Care
680. Sato Pharmaceutical
681. SAVA Healthcare
682. Savior Lifetec
683. Schering-Plough
684. SCI Pharmtech
685. Scientific Protein Laboratories
686. ScinoPharm
687. SEA Vision
688. Seacross Pharmaceuticals
689. Sekisui Medical
690. Selvok Pharmaceutical
691. Senn Chemicals
692. Sensilab®
693. Sentiss Pharma
694. Sesderma Group
695. Shandong Xinhua Pharmaceutical
696. Shanghai Pharmaceuticals Holding
697. Shanghai Shyndec Pharmaceutical
698. Sharon Bio-Medicine
699. Shasun Pharmaceuticals
700. Shilpa Medicare
701. Shionogi
702. Shire
703. Sichuan Huiyu Pharmaceutical
704. Siegfried
705. Sigmapharm Laboratories
706. SignaGen Laboratories
707. Singota Solutions
708. Sinopharm
709. Sirio Pharma
710. SM Pharmaceuticals
711. Smruthi Organics
712. SMS Pharmaceuticals
713. Societa Italiana Medicinali Scandicci
714. Softgel Healthcare
715. Softigel
716. SOHO Global Health
717. Solitaire Pharmacia
718. Sovereign Pharma
719. Square Pharmaceuticals
720. Sricure Herbs
721. ST Pharm
722. STA Pharmaceutical
723. STADA Arzneimittel
724. Stason Pharmaceuticals
725. Stericon
726. Steril-Gene Life Sciences
727. Strides Shasun
728. Sunrise International Labs
729. Sunrise Pharma
730. Sunways
731. Suven Life Sciences
732. Suzuken
733. Swiss Pharma
734. Symbiosis Pharmaceutical Services
735. Symed Labs
736. Synbias Pharma
737. SynCo Bio Partners
738. Syncom Healthcare
739. Syngene International
740. SYNLAB Group
741. Syntech Pharmachem
742. Synthokem Labs
743. Syntonix Biofarm
744. Tahira Industries India
745. Tai Heng Industry
746. Takara Bio
747. Tara Innovations
748. Tedor Pharma
749. Teligent
750. TESARO
751. Teva Active Pharmaceutical Ingredients (TAPI)
752. The Carlyle Group
753. The Native Antigen Company
754. The Ritedose
755. Theon Pharmaceuticals
756. Therapeutic Goods Administration (TGA)
757. Therapure Biopharma
758. Thermo Fisher Scientific
759. Tianjin Pharmaceutical Group
760. Tillotts Pharma
761. Time-Cap Labs
762. Titan Pharma
763. TOLMAR
764. Tonus-Les
765. Torrent Pharmaceuticals
766. Toyobo Biologics
767. TraceLink
768. TranXenoGen
769. trenzyme
770. Tubilux Pharma
771. Tyger Scientific
772. Ultra Tab Laboratories
773. Ultratech India
774. Unibiotech Formulations
775. Unichem Laboratories
776. Unimark Remedies
777. Union Quimico Farmaceutica (UQUIFA)
778. Unison Chemical Works
779. United States Food and Drug Administration (USFDA)
780. University of Alabama
781. University of Minnesota
782. University of Nebraska
783. University of Newcastle
784. University of Pennsylvania
785. University of Utah
786. UPM Pharmaceuticals
787. Uppsala University Hospital
788. URSAPHARM Arzneimittel
789. US Pharma Lab
790. USV
791. Valeant Pharmaceuticals International
792. Veeva Systems
793. Vendiz Pharmaceuticals
794. VerGo Pharma Research
795. Vertex Pharmaceuticals
796. Vetter Pharma
797. VGXI
798. Vibalogics
799. Vigene Biosciences
800. Virbac
801. Virovek
802. Vista Biologicals
803. Vital Health Care
804. Vivimed Labs
805. VUAB Pharma
806. WACKER Biotech
807. Waisman Biomanufacturing
808. Wanbury
809. WellSpring Pharmaceutical
810. West Pharmaceutical Services
811. WeylChem Group
812. Wilmington PharmaTech
813. Windlas Healthcare
814. Wintac
815. Wisdom Pharmaceutical
816. Wockhardt
817. World Health Organization (WHO)
818. World Intellectual Property Organization (WIPO)
819. World Trade Organization (WTO)
820. Wuhan Biocause Pharmaceutical Development
821. WuXi AppTec
822. WuXi NextCODE
823. Xellia Pharmaceuticals
824. Xi'an Lijun Pharmaceutical
825. XtalPi
826. Xttrium Laboratories
827. YaoPharma
828. Yash Pharma Laboratories
829. Yung Zip Chemical
830. Zach System
831. Zambon
832. Zenacts Pharma
833. Zenara Pharma
834. Zenith Healthcare
835. ZenLabs Ethica
836. ZheJiang Apeloa JiaYuan Pharmaceutical
837. Zhejiang Changming Pharmaceutical
838. Zhejiang Cheng Yi Pharmaceutical
839. Zhejiang Excel Pharmaceutical
840. Zhejiang Hisun Pharmaceutical
841. Zhejiang Huahai Pharmaceutical
842. Zhejiang Huangyan Fine Chemical Group
843. Zhejiang Jingxin Pharmaceutical
844. Zydus BSV Pharma
845. Zydus Cadila


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Manufacturers in the Contract Manufacturing Industry
3.3. An Overview of the Pharmaceutical Contract Manufacturing Industry
3.4. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.4.1. Early Phase: Role of Traditional CMOs
3.4.2. Emerging Phase: Role of Modern CMOs
3.5. The Need for Outsourcing in the Pharmaceutical Industry
3.6. Contract Manufacturing Models
3.6.1. Tactical Partnership
3.6.2. Integrated End-to-End Business Model
3.6.3. Strategic Long-Term Alliance
3.6.4. Flexible Short-Term Partnership
3.6.5. Innovation Driven Contract Manufacturing
3.7. Services Offered by CMOs
3.8. Selecting a CMO Partner
3.9. Risks and Challenges in Contract Manufacturing Industry
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Pharmaceutical CMOs: List of Industry Players
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Company Size
4.2.4. Distribution by Type of Business Segment
4.2.5. Distribution by Type of FDF Offered
4.2.6. Distribution by Scale of Operation
4.2.7. Distribution by Type of Service Offering
4.2.8. Distribution by Location of Manufacturing Facilities
4.2.9. Distribution by Type of Primary Packaging Form Offered
5. REGULATORY LANDSCAPE FOR PHARMACEUTICAL CONTRACT MANUFACTURERS
5.1. Chapter Overview
5.2. Regulatory Guidelines in North America
5.2.1. The US Scenario
5.2.2. Canadian Scenario
5.3. Regulatory Guidelines in Europe
5.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
5.4.1. Chinese Scenario
5.4.2. Indian Scenario
5.4.3. Japanese Scenario
5.4.4. South Korean Scenario
5.4.5. Australian Scenario
5.4.6. Brazilian Scenario
5.5. Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
5.6. Regulatory Landscape of Pharmaceutical Contract Manufacturing: Bubble Analysis by Regions
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Importance of One-Stop-Shops
6.3. Company Profiles of One-Stop-Shops
6.4. Players in North America
6.4.1. Albany Molecular Research (AMRI)
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Financial Information
6.4.1.4. Manufacturing Capabilities and Facilities
6.4.1.5. Recent Developments
6.4.1.6. Future Outlook
6.4.2. Catalent®
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Financial Information
6.4.2.4. Manufacturing Capabilities and Facilities
6.4.2.5. Recent Developments
6.4.2.6. Future Outlook
6.4.3. DPT® Laboratories
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Capabilities and Facilities
6.4.3.4. Recent Developments
6.4.3.5. Future Outlook
6.4.4. Thermo Fisher Scientific (Through Acquisition of Patheon®)
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Financial Information
6.4.4.4. Manufacturing Capabilities and Facilities
6.4.4.5. Recent Developments
6.4.4.6. Future Outlook
6.5. Players in Europe
6.5.1. Aenova Group
6.5.1.1. Company Overview
6.5.1.2. Service Portfolio
6.5.1.3. Financial Information
6.5.1.4. Manufacturing Capabilities and Facilities
6.5.1.5. Recent Developments
6.5.1.6. Future Outlook
6.5.2. Almac Group
6.5.2.1. Company Overview
6.5.2.2. Service Portfolio
6.5.2.3. Recent Developments
6.5.2.4. Future Outlook
6.5.3. CordenPharma
6.5.3.1. Company Overview
6.5.3.2. Service Portfolio
6.5.3.3. Manufacturing Capabilities and Facilities
6.5.3.4. Recent Developments
6.5.3.5. Future Outlook
6.5.4. Fresenius Kabi
6.5.4.1. Company Overview
6.5.4.2. Service Portfolio
6.5.4.3. Financial Information
6.5.4.4. Manufacturing Capabilities and Facilities
6.5.4.5. Recent Developments
6.5.4.6. Future Outlook
6.5.5. Glatt®
6.5.5.1. Company Overview
6.5.5.2. Service Portfolio
6.5.5.3. Manufacturing Capabilities and Facilities
6.5.5.4. Recent Developments
6.5.5.5. Future Outlook
6.5.6. Groupe SYNERLAB
6.5.6.1. Company Overview
6.5.6.2. Service Portfolio
6.5.6.3. Manufacturing Capabilities and Facilities
6.5.6.4. Future Outlook
6.5.7. Hovione
6.5.7.1. Company Overview
6.5.7.2. Service Portfolio
6.5.7.3. Manufacturing Capabilities and Facilities
6.5.7.4. Recent Developments
6.5.7.5. Future Outlook
6.5.8. Recipharm
6.5.8.1. Company Overview
6.5.8.2. Service Portfolio
6.5.8.3. Financial Information
6.5.8.4. Manufacturing Capabilities and Facilities
6.5.8.5. Recent Developments
6.5.8.6. Future Outlook
6.5.9. Siegfried
6.5.9.1. Company Overview
6.5.9.2. Service Portfolio
6.5.9.3. Financial Information
6.5.9.4. Manufacturing Capabilities and Facilities
6.5.9.5. Recent Developments
6.5.9.6. Future Outlook
6.6. Players in Asia
6.6.1. CMIC Group
6.6.1.1. Company Overview
6.6.1.2. Service Portfolio
6.6.1.3. Financial Information
6.6.1.4. Manufacturing Capabilities and Facilities
6.6.1.5. Recent Developments
6.6.1.6. Future Outlook
6.6.2. Nectar Lifesciences
6.6.2.1. Company Overview
6.6.2.2. Service Portfolio
6.6.2.3. Financial Information
6.6.2.4. Manufacturing Capabilities and Facilities
6.6.2.5. Future Outlook
6.6.3. WuXi AppTec
6.6.3.1. Company Overview
6.6.3.2. Service Portfolio
6.6.3.3. Financial Information
6.6.3.4. Manufacturing Capabilities and Facilities
6.6.3.5. Recent Developments
6.6.3.6. Future Outlook
7. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
7.1. Chapter Overview
7.2. Small Molecules and Large Molecules: An Introduction
7.2.1. Comparison of Key Characteristics
7.2.2. Comparison of Manufacturing Processes
7.2.3. Comparison of Key Manufacturing Challenges
7.3. Manufacturing of Large Molecules (Biologics): List of Biopharmaceutical CMOs
8. KEY INSIGHTS
8.1. Chapter Overview
8.2. Integrated Service Providers: Heat Map Analysis
8.3. Pharmaceutical CMOs: Geographical Landscape
8.4. Pharmaceutical CMOs: Analysis by Geography, Company Size and Business Segment
9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Pharmaceutical Contract Manufacturing: Installed Global Capacity
9.3.1. Distribution by Size of CMOs
9.3.2. Distribution by Scale of Operation
9.3.3. Distribution by Location of Headquarters
9.3.4. Distribution by Location of Manufacturing Facilities
9.4. Concluding Remarks
10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Pharmaceutical Contract Manufacturing Market, 2018-2028
10.3.1. Pharmaceutical Contract Manufacturing Market for API Manufacturing, 2018-2028
10.3.2. Pharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2018-2028
10.4. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions
10.4.1. Pharmaceutical Contract Manufacturing Market in North America, 2018-2028
10.4.2. Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028
10.4.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028
10.4.4. Pharmaceutical Contract Manufacturing Market in Rest of the World, 2018-2028
10.4.5. Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions
10.5. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product
10.6. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF
10.7. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form
10.8. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API
10.9. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers
10.10 Concluding Remarks
11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats
11.6. Comparison of SWOT Factors
12. FUTURE OF THE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
12.1. Chapter Overview
12.2. Anticipated Growth in Outsourcing Activities
12.3. Growing Focus on Emerging Markets
12.4. Shift Towards an Integrated Business Model
12.5. Expansion of Capabilities and Emergence of One-Stop-Shops
12.6. Adoption of New Technologies and Focus on Innovation to Support Further Growth
12.7. Use of Big Data and Advanced Analytics to Improve Manufacturing Processes
12.8. Implementation of Cybersecurity Solutions to Safeguard Valuable Customer Data
12.9. Growing Demand for Biologics and Biosimilars
12.10. Escalating Demand for Services in High Potency and Cytotoxic Drugs Manufacturing
12.11. Concluding Remarks
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Ajinomoto Althea
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Scott Goldstein, Associate Director, Drug Product Manufacturing
13.3. Bachem
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Thomas Früh, Chief Executive Officer
13.4. Sovereign Pharma
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Piyush Desai, Director, Operations
13.5. Batavia Biosciences
13.5.1. Company Snapshot
13.5.2. Interview Transcript: Claire Otjes, Assistant Marketing Manager
13.6. Polymun Scientific
13.6.1. Company Snapshot
13.6.2. Interview Transcript: Birgit Schwab (Senior Manager Strategic Marketing
13.7. Rentschler Biopharma
13.7.1. Company Snapshot
13.7.2. Interview Transcript: Birgit Schwab, Senior Manager Strategic Marketing
13.8. WACKER Biotech
13.8.1. Company Snapshot
13.8.2. Interview Transcript: Sebastian Schuck, Head of Business Development
13.9. CiVentiChem
13.9.1. Company Snapshot
13.9.2. Interview Transcript: Bhaskar VenePalli, President and Chief Executive Officer
13.10. CordenPharma
13.10.1. Company Snapshot
13.10.2. Interview Transcript: Roberto Margartia, Business Development Director
13.11. Helsinn Group
13.11.1. Company Snapshot
13.11.2. Interview Transcript: Allison Vavala, Senior Manager, Business Development
13.12. Novasep
13.12.1. Company Snapshot
13.12.2. Interview Transcript: Kevin Daley, Market Director Pharmaceuticals
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Types of Manufacturers in Contract Manufacturing Industry
Figure 3.2 Types of Third Party Service Providers in Contract Manufacturing Industry
Figure 3.3 Outsourcing across Various Components of Pharmaceutical Value Chain
Figure 3.4 Range of Services Offered by CMOs
Figure 3.5 Factors for Selecting a CMO Partner
Figure 3.6 Risks and Challenges Associated with Contract Manufacturing Industry
Figure 4.1 Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 4.2 Pharmaceutical CMOs: Distribution by Geographical Location
Figure 4.3 Pharmaceutical CMOs: Regional Hubs
Figure 4.4 Pharmaceutical CMOs: Distribution by Company Size
Figure 4.5 Pharmaceutical CMOs: Distribution by Type of Business Segment
Figure 4.6 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Figure 4.7 Pharmaceutical CMOs: Distribution by Scale of Operation
Figure 4.8 Pharmaceutical CMOs: Distribution by Type of Service Offering
Figure 4.9 Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
Figure 4.10 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Form Offered
Figure 5.1 Key Regulatory Requirements for CMOs and CROs in India
Figure 5.2 Regulatory Landscape for Pharmaceutical CMOs: Analysis by Type of Regulatory Authorities
Figure 5.3 Regulatory Landscape of Pharmaceutical Contract Manufacturing: Bubble Analysis by Regions
Figure 6.1 AMRI: Service Portfolio
Figure 6.2 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 6.3 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Figure 6.4 Catalent®: Service Portfolio
Figure 6.5 Catalent®: Annual Revenues, 2013-Q2 2018 (USD Million)
Figure 6.6 DPT® Laboratories: Service Portfolio
Figure 6.7 Patheon®: Service Portfolio
Figure 6.8 Thermo Fisher Scientific: Annual Revenues, 2013-2017 (USD Billion)
Figure 6.9 Thermo Fisher Scientific: Revenues by Business Segments, 2016 (USD Billion)
Figure 6.10 Patheon®: Annual Revenues, 2012-H1 2017 (USD Million)
Figure 6.11 Patheon®: Revenues by Business Segments, 2016 (USD Million)
Figure 6.12 Aenova Group: Service Portfolio
Figure 6.13 Almac Group: Service Portfolio
Figure 6.14 CordenPharma: Service Portfolio
Figure 6.15 Fresenius Kabi: Service Portfolio
Figure 6.16 Fresenius Kabi: Annual Revenues, 2013-2017 (EUR Million)
Figure 6.17 Fresenius Kabi: Revenues by Product Segments, 2016 (EUR Million)
Figure 6.18 Glatt®: Service Portfolio
Figure 6.19 Groupe SYNERLAB: Service Portfolio
Figure 6.20 Hovione: Service Portfolio
Figure 6.21 Recipharm: Service Portfolio
Figure 6.22 Recipharm: Annual Revenues, 2013-2017 (SEK Million)
Figure 6.23 Recipharm: Revenues by Business Segments, 2017 (SEK Million)
Figure 6.24 Siegfried: Service Portfolio
Figure 6.25 Siegfried: Annual Revenues, 2012-H1 2017 (CHF Million)
Figure 6.26 Siegfried: Revenues by Product Segments, 2016 (CHF Million)
Figure 6.27 CMIC Group: Service Portfolio
Figure 6.28 CMIC Group: Annual Revenues, 2013-Q1 2018 (JPY Million)
Figure 6.29 Nectar Lifesciences: Service Portfolio
Figure 6.30 Nectar Lifesciences: Annual Revenues, 2012-Q3 2017 (INR Billion)
Figure 6.31 WuXi AppTec: Service Portfolio
Figure 6.32 STA Pharmaceuticals (API Service Provider, WuXi AppTec): Service Portfolio
Figure 6.33 WuXi AppTec: Revenues (USD Million)
Figure 7.1 Small Molecules versus Large Molecules: Comparison of Key Characteristics
Figure 7.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Processes
Figure 7.3 Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Figure 8.1 Integrated Service Providers, Heat Map Analysis: Distribution by Geography, Company Size and Year of Establishment
Figure 8.2 Pharmaceutical CMOs: Geographical Landscape Analysis by Location of Manufacturing Facilities
Figure 8.3 Pharmaceutical CMOs: Distribution by Geography, Company Size and Business Segment
Figure 9.1 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Figure 9.2 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Location of Headquarters (Sample Data Set)
Figure 9.3 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Figure 9.4 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Figure 9.5 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Headquarters
Figure 9.6 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 9.7 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 10.1 Pharmaceutical Contract Manufacturing: Market Forecast Approach
Figure 10.2 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Base Scenario (USD Billion)
Figure 10.3 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Base Scenario (USD Billion)
Figure 10.4 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.5 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Base Scenario (USD Billion)
Figure 10.6 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Base Scenario (Volume, Liter)
Figure 10.7 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Base Scenario (USD Billion)
Figure 10.8 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Base Scenario (Volume, Liter)
Figure 10.9 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Base Scenario (USD Billion)
Figure 10.10 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Base Scenario (Volume, Liter)
Figure 10.11 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Base Scenario (USD Billion)
Figure 10.12 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Base Scenario (Volume, Liter)
Figure 10.13 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Base Scenario (USD Billion)
Figure 10.14 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Base Scenario (Volume, Liter)
Figure 10.15 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (USD Billion)
Figure 10.16 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (Volume, Liter)
Figure 10.17 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Base Scenario (USD Billion)
Figure 10.18 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product and Regions, Base Scenario (USD Billion)
Figure 10.19 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Base Scenario (USD Billion)
Figure 10.20 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Base Scenario (USD Billion)
Figure 10.21 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Base Scenario (USD Billion)
Figure 10.22 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Base Scenario (USD Billion)
Figure 10.23 Overall Pharmaceutical Contract Manufacturing Market: Comparative Evolution Scenarios, 2018 and 2028 (USD Billion)
Figure 11.1 Pharmaceutical Contract Manufacturing SWOT Analysis: Overview
Figure 11.2 Pharmaceutical Contract Manufacturing SWOT Analysis: Strengths
Figure 11.3 Pharmaceutical Contract Manufacturing SWOT Analysis: Weaknesses
Figure 11.4 Pharmaceutical Contract Manufacturing SWOT Analysis: Opportunities
Figure 11.5 Pharmaceutical Contract Manufacturing SWOT Analysis: Threats
Figure 11.6 Pharmaceutical Contract Manufacturing SWOT Analysis: Comparison of SWOT Factors by Potential Impact
Figure 11.7 Pharmaceutical Contract Manufacturing SWOT Analysis: Comparison of SWOT Factors, Harvey Ball Analysis
Figure 12.1 Future of Pharmaceutical Contract Manufacturing Market
Figure 12.2 Emerging Markets in Pharmaceutical Contract Manufacturing Industry
LIST OF TABLES
Table 4.1 Pharmaceutical CMOs: List of Industry Players
Table 4.2 Pharmaceutical CMOs: Information on Type of FDF Offered
Table 4.3 Pharmaceutical CMOs: Information on Scale of Operation
Table 4.4 Pharmaceutical CMOs: Information on Type of Service Offering
Table 4.5 Pharmaceutical CMOs: Information on Location of Manufacturing Facilities
Table 4.6 Pharmaceutical CMOs: Information on Type of Primary Packaging Form Offered
Table 5.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
Table 5.2 Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
Table 6.1 Pharmaceutical Contract Manufacturing: List of Companies Profiled
Table 6.2 AMRI: Manufacturing Facilities
Table 6.3 AMRI: Sterile Manufacturing Facilities
Table 6.4 AMRI: Recent Collaborations
Table 6.5 AMRI: Recent Expansions
Table 6.6 Catalent®: Manufacturing Facilities
Table 6.7 Catalent®: Recent Collaborations
Table 6.8 Catalent®: Recent Expansions
Table 6.9 DPT® Laboratories: Manufacturing Facilities
Table 6.10 DPT® Laboratories: Recent Collaborations
Table 6.11 DPT® Laboratories: Recent Expansions
Table 6.12 Patheon®: Manufacturing Facilities
Table 6.13 Patheon®: Recent Collaborations
Table 6.14 Patheon®: Recent Expansions
Table 6.15 Aenova Group: Manufacturing Facilities
Table 6.16 Aenova Group: Drug Product Manufacturing Capabilities
Table 6.17 Aenova Group: Recent Expansions
Table 6.18 Almac Group: Recent Collaborations
Table 6.19 Almac Group: Recent Expansions
Table 6.20 CordenPharma: Manufacturing Facilities
Table 6.21 CordenPharma: Recent Collaborations
Table 6.22 CordenPharma: Recent Expansions
Table 6.23 Fresenius Kabi: Manufacturing Facilities
Table 6.24 Fresenius Kabi: Drug Product Manufacturing Capabilities
Table 6.25 Fresenius Kabi: Recent Collaborations
Table 6.26 Fresenius Kabi: Recent Expansions
Table 6.27 Glatt®: Manufacturing Facilities
Table 6.28 Glatt®: Recent Expansions
Table 6.29 Groupe SYNERLAB: Manufacturing Facilities
Table 6.30 Hovione: Manufacturing Facilities
Table 6.31 Hovione: Recent Collaborations
Table 6.32 Hovione: Recent Expansions
Table 6.33 Recipharm: Manufacturing Facilities
Table 6.34 Recipharm: Recent Collaborations
Table 6.35 Recipharm: Recent Expansions
Table 6.36 Siegfried: Manufacturing Facilities
Table 6.37 Siegfried: Recent Collaborations
Table 6.38 CMIC Group: Manufacturing Facilities
Table 6.39 CMIC Group: Recent Collaborations
Table 6.40 CMIC Group: Recent Expansions
Table 6.41 Nectar Lifesciences: Manufacturing Facilities
Table 6.42 WuXi AppTec: Manufacturing Facilities
Table 6.43 WuXi AppTec: Recent Collaborations
Table 6.44 WuXi AppTec: Recent Expansions
Table 7.1 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 7.2 List of Biopharmaceutical CMOs
Table 9.1 Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
Table 9.2 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Table 9.3 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 13.1 Ajinomoto Althea: Key Highlights
Table 13.2 Bachem: Key Highlights
Table 13.3 Sovereign Pharma: Key Highlights
Table 13.4 Batavia Biosciences: Key Highlights
Table 13.5 Polymun Scientific: Key Highlights
Table 13.6 Rentschler Biopharma: Key Highlights
Table 13.7 WACKER Biotech: Key Highlights
Table 13.8 CiVentiChem: Key Highlights
Table 13.9 Helsinn Group: Key Highlights
Table 13.10 Novasep: Key Highlights
Table 14.1 Pharmaceutical CMOs: Distribution by Year of Establishment
Table 14.2 Pharmaceutical CMOs: Distribution by Geographical Location
Table 14.3 Pharmaceutical CMOs: Distribution by Company Size
Table 14.4 Pharmaceutical CMOs: Distribution by Type of Business Segment
Table 14.5 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Table 14.6 Pharmaceutical CMOs: Distribution by Scale of Operation
Table 14.7 Pharmaceutical CMOs: Distribution by Service Offerings
Table 14.8 Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
Table 14.9 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Form Offered
Table 14.10 Regulatory Landscape for Pharmaceutical CMOs: Analysis by Type of Regulatory Authorities
Table 14.11 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 14.12 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Table 14.13 Catalent®: Annual Revenues, 2013-Q2 2018 (USD Million)
Table 14.14 Thermo Fisher Scientific: Annual Revenues, 2013-2017 (USD Billion)
Table 14.15 Thermo Fisher Scientific: Revenues by Business Segments, 2016 (USD Billion)
Table 14.16 Patheon®: Annual Revenues, 2012-H1 2017 (USD Million)
Table 14.17 Patheon®: Revenues by Business Segments, 2016 (USD Million)
Table 14.18 Fresenius Kabi: Annual Revenues, 2013-2017 (EUR Million)
Table 14.19 Fresenius Kabi: Revenues by Product Segments, 2016 (EUR Million)
Table 14.20 Recipharm: Annual Revenues, 2013-2017 (SEK Million)
Table 14.21 Recipharm: Revenues by Business Segments, 2017 (SEK Million)
Table 14.22 Siegfried: Annual Revenues, 2012-H1 2017 (CHF Million)
Table 14.23 Siegfried: Revenues by Product Segments, 2016 (CHF Million)
Table 14.24 CMIC Group: Annual Revenues, 2013-Q1 2018 (JPY Million)
Table 14.25 Nectar Lifesciences: Annual Revenues, 2012-Q3 2017 (INR Billion)
Table 14.26 WuXi AppTec: Revenues (USD Million)
Table 14.27 Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Table 14.28 Pharmaceutical CMOs: Distribution by Geography, Company Size and Business Segment
Table 14.29 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Table 14.30 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Location of Headquarters (Sample Data Set)
Table 14.31 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 14.32 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Table 14.33 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Headquarters
Table 14.34 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Region-wise)
Table 14.35 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 14.36 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Conservative Scenario (USD Billion)
Table 14.37 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Base Scenario (USD Billion)
Table 14.38 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.39 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Conservative Scenario (USD Billion)
Table 14.40 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Base Scenario (USD Billion)
Table 14.41 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.42 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Conservative Scenario (USD Billion)
Table 14.43 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Base Scenario (USD Billion)
Table 14.44 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.45 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Conservative Scenario (USD Billion)
Table 14.46 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Base Scenario (USD Billion)
Table 14.47 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Optimistic Scenario (USD Billion)
Table 14.48 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Conservative Scenario (Volume, Liter)
Table 14.49 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Base Scenario (Volume, Liter)
Table 14.50 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Optimistic Scenario (Volume, Liter)
Table 14.51 Pharmaceutical Contract Manufacturing Market, 2018-2028: US, Conservative Scenario (Volume, Liter)
Table 14.52 Pharmaceutical Contract Manufacturing Market, 2018-2028: US, Base Scenario (Volume, Liter)
Table 14.53 Pharmaceutical Contract Manufacturing Market, 2018-2028: US, Optimistic Scenario (Volume, Liter)
Table 14.54 Pharmaceutical Contract Manufacturing Market, 2018-2028: Canada, Conservative Scenario (Volume, Liter)
Table 14.55 Pharmaceutical Contract Manufacturing Market, 2018-2028: Canada, Base Scenario (Volume, Liter)
Table 14.56 Pharmaceutical Contract Manufacturing Market, 2018-2028: Canada, Optimistic Scenario (Volume, Liter)
Table 14.57 Pharmaceutical Contract Manufacturing Market, 2018-2028: Mexico, Conservative Scenario (Volume, Liter)
Table 14.58 Pharmaceutical Contract Manufacturing Market, 2018-2028: Mexico, Base Scenario (Volume, Liter)
Table 14.59 Pharmaceutical Contract Manufacturing Market, 2018-2028: Mexico, Optimistic Scenario (Volume, Liter)
Table 14.60 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Conservative Scenario (USD Billion)
Table 14.61 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Base Scenario (USD Billion)
Table 14.62 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Optimistic Scenario (USD Billion)
Table 14.63 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Conservative Scenario (Volume, Liter)
Table 14.64 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Base Scenario (Volume, Liter)
Table 14.65 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Optimistic Scenario (Volume, Liter)
Table 14.66 Pharmaceutical Contract Manufacturing Market, 2018-2028: Italy, Conservative Scenario (Volume, Liter)
Table 14.67 Pharmaceutical Contract Manufacturing Market, 2018-2028: Italy, Base Scenario (Volume, Liter)
Table 14.68 Pharmaceutical Contract Manufacturing Market, 2018-2028: Italy, Optimistic Scenario (Volume, Liter)
Table 14.69 Pharmaceutical Contract Manufacturing Market, 2018-2028: Germany, Conservative Scenario (Volume, Liter)
Table 14.70 Pharmaceutical Contract Manufacturing Market, 2018-2028: Germany, Base Scenario (Volume, Liter)
Table 14.71 Pharmaceutical Contract Manufacturing Market, 2018-2028: Germany, Optimistic Scenario (Volume, Liter)
Table 14.72 Pharmaceutical Contract Manufacturing Market, 2018-2028: France, Conservative Scenario (Volume, Liter)
Table 14.73 Pharmaceutical Contract Manufacturing Market, 2018-2028: France, Base Scenario (Volume, Liter)
Table 14.74 Pharmaceutical Contract Manufacturing Market, 2018-2028: France, Optimistic Scenario (Volume, Liter)
Table 14.75 Pharmaceutical Contract Manufacturing Market, 2018-2028: Spain, Conservative Scenario (Volume, Liter)
Table 14.76 Pharmaceutical Contract Manufacturing Market, 2018-2028: Spain, Base Scenario (Volume, Liter)
Table 14.77 Pharmaceutical Contract Manufacturing Market, 2018-2028: Spain, Optimistic Scenario (Volume, Liter)
Table 14.78 Pharmaceutical Contract Manufacturing Market, 2018-2028: UK, Conservative Scenario (Volume, Liter)
Table 14.79 Pharmaceutical Contract Manufacturing Market, 2018-2028: UK, Base Scenario (Volume, Liter)
Table 14.80 Pharmaceutical Contract Manufacturing Market, 2018-2028: UK, Optimistic Scenario (Volume, Liter)
Table 14.81 Pharmaceutical Contract Manufacturing Market, 2018-2028: Other European Countries, Conservative Scenario (Volume, Liter)
Table 14.82 Pharmaceutical Contract Manufacturing Market, 2018-2028: Other European Countries, Base Scenario (Volume, Liter)
Table 14.83 Pharmaceutical Contract Manufacturing Market, 2018-2028: Other European Countries, Optimistic Scenario (Volume, Liter)
Table 14.84 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Conservative Scenario (USD Billion)
Table 14.85 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Base Scenario (USD Billion)
Table 14.86 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Optimistic Scenario (USD Billion)
Table 14.87 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Conservative Scenario (Volume, Liter)
Table 14.88 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Base Scenario (Volume, Liter)
Table 14.89 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Optimistic Scenario (Volume, Liter)
Table 14.90 Pharmaceutical Contract Manufacturing Market, 2018-2028: China, Conservative Scenario (Volume, Liter)
Table 14.91 Pharmaceutical Contract Manufacturing Market, 2018-2028: China, Base Scenario (Volume, Liter)
Table 14.92 Pharmaceutical Contract Manufacturing Market, 2018-2028: China, Optimistic Scenario (Volume, Liter)
Table 14.93 Pharmaceutical Contract Manufacturing Market, 2018-2028: India, Conservative Scenario (Volume, Liter)
Table 14.94 Pharmaceutical Contract Manufacturing Market, 2018-2028: India, Base Scenario (Volume, Liter)
Table 14.95 Pharmaceutical Contract Manufacturing Market, 2018-2028: India, Optimistic Scenario (Volume, Liter)
Table 14.96 Pharmaceutical Contract Manufacturing Market, 2018-2028: Japan, Conservative Scenario (Volume, Liter)
Table 14.97 Pharmaceutical Contract Manufacturing Market, 2018-2028: Japan, Base Scenario (Volume, Liter)
Table 14.98 Pharmaceutical Contract Manufacturing Market, 2018-2028: Japan, Optimistic Scenario (Volume, Liter)
Table 14.99 Pharmaceutical Contract Manufacturing Market, 2018-2028: Australia, Conservative Scenario (Volume, Liter)
Table 14.100 Pharmaceutical Contract Manufacturing Market, 2018-2028: Australia, Base Scenario (Volume, Liter)
Table 14.101 Pharmaceutical Contract Manufacturing Market, 2018-2028: Australia, Optimistic Scenario (Volume, Liter)
Table 14.102 Pharmaceutical Contract Manufacturing Market, 2018-2028: Other Asia-Pacific Countries, Conservative Scenario (Volume, Liter)
Table 14.103 Pharmaceutical Contract Manufacturing Market, 2018-2028: Other Asia-Pacific Countries, Base Scenario (Volume, Liter)
Table 14.104 Pharmaceutical Contract Manufacturing Market, 2018-2028: Other Asia-Pacific Countries, Optimistic Scenario (Volume, Liter)
Table 14.105 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Conservative Scenario (USD Billion)
Table 14.106 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Base Scenario (USD Billion)
Table 14.107 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Optimistic Scenario (USD Billion)
Table 14.108 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Conservative Scenario (Volume, Liter)
Table 14.109 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Base Scenario (Volume, Liter)
Table 14.110 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Optimistic Scenario (Volume, Liter)
Table 14.111 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (USD Billion)
Table 14.112 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (Volume, Liter)
Table 14.113 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Conservative Scenario (USD Billion)
Table 14.114 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Base Scenario (USD Billion)
Table 14.115 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution of by Types of API Product, Optimistic Scenario (USD Billion)
Table 14.116 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in North America, Conservative Scenario (USD Billion)
Table 14.117 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in North America, Base Scenario (USD Billion)
Table 14.118 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution of by Type of API Product in North America, Optimistic Scenario (USD Billion)
Table 14.119 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Conservative Scenario (USD Billion)
Table 14.120 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Base Scenario (USD Billion)
Table 14.121 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Optimistic Scenario (USD Billion)
Table 14.122 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Conservative Scenario (USD Billion)
Table 14.123 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Base Scenario (USD Billion)
Table 14.124 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Optimistic Scenario (USD Billion)
Table 14.125 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Conservative Scenario (USD Billion)
Table 14.126 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Base Scenario (USD Billion)
Table 14.127 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Optimistic Scenario (USD Billion)
Table 14.128 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Conservative Scenario (USD Billion)
Table 14.129 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Base Scenario (USD Billion)
Table 14.130 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Optimistic Scenario (USD Billion)
Table 14.131 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Conservative Scenario (USD Billion)
Table 14.132 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Base Scenario (USD Billion)
Table 14.133 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Optimistic Scenario (USD Billion)
Table 14.134 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Conservative Scenario (USD Billion)
Table 14.135 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Base Scenario (USD Billion)
Table 14.136 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Optimistic Scenario (USD Billion)
Table 14.137 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Conservative Scenario (USD Billion)
Table 14.138 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Base Scenario (USD Billion)
Table 14.139 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Optimistic Scenario (USD Billion)
Table 14.140 Overall Pharmaceutical Contract Manufacturing Market: Comparative Evolution Scenarios, 2018 and 2028 (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report